Shaunak Navalkissoor
Overview
Explore the profile of Shaunak Navalkissoor including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
60
Citations
451
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Navalkissoor S, Millar R
J Neuroendocrinol
. 2025 Mar;
:e70014.
PMID: 40024622
No abstract available.
2.
Ponna N, Luong T, Navalkissoor S
Clin Nucl Med
. 2025 Jan;
PMID: 39854675
A 57-year-old man with a 3-month history of lower abdominal pain and rectal bleeding with black stools underwent urgent abdominal CT, which revealed an ovoid hyperdense lesion in the ileum...
3.
Navalkissoor S, Grossman A
J Neuroendocrinol
. 2024 Nov;
:e13463.
PMID: 39529416
The incidence and prevalence of neuroendocrine tumours (NETs) are on the rise, but to date, only complete surgical resection is curative. Among the various therapeutic options for metastatic disease, peptide...
4.
Buscombe J, Cwikla J, Quigley A, Navalkissoor S, Yu D
Semin Nucl Med
. 2024 Apr;
54(4):530-536.
PMID: 38627159
Selective intra-arterial radiotherapy (SIRT) is a technique which has evolved over the past 30 years. In present this is primarily used to treat primary and secondary tumors in the liver....
5.
Schurrle S, Eberlein U, Ansquer C, Beauregard J, Durand-Gasselin L, Gronbaek H, et al.
Eur J Nucl Med Mol Imaging
. 2024 Mar;
51(8):2428-2441.
PMID: 38528164
Purpose: To evaluate the dosimetry and pharmacokinetics of the novel radiolabelled somatostatin receptor antagonist [Lu]Lu-satoreotide tetraxetan in patients with advanced neuroendocrine tumours (NETs). Methods: This study was part of a...
6.
Chan D, Hayes A, Karfis I, Conner A, Mileva M, Bernard E, et al.
J Nucl Med
. 2024 Jan;
65(2):185-191.
PMID: 38164579
[F]FDG PET/CT and [Ga]Ga-DOTATATE PET/CT are both used to predict tumor biology in neuroendocrine neoplasms. Although the presence of discordant ([F]FDG-avid/non-[Ga]Ga-DOTATATE-avid) disease predicts poor prognosis, the significance of the volume...
7.
Wild D, Gronbaek H, Navalkissoor S, Haug A, Nicolas G, Pais B, et al.
Eur J Nucl Med Mol Imaging
. 2023 Sep;
51(1):183-195.
PMID: 37721581
Purpose: We present the results of an open-label, phase I/II study evaluating the safety and efficacy of the novel somatostatin receptor (SSTR) antagonist [Lu]Lu-satoreotide tetraxetan in 40 patients with previously...
8.
Alsadik S, Gnanasegaran G, Chen L, Quigley A, Mandair D, Toumpanakis C, et al.
Clin Nucl Med
. 2023 May;
48(8):667-672.
PMID: 37167406
Aim: The aim of this study was to assess the efficacy and safety of 177 Lu-DOTATATE in patients with neuroendocrine tumors (NETs) and extensive bone metastases, that is, more than...
9.
Chan D, Hayes A, Karfis I, Conner A, OMahony L, Mileva M, et al.
Br J Cancer
. 2022 Nov;
128(4):549-555.
PMID: 36434154
Background: Gastroenteropancreatic neuroendocrine neoplasms (GEPNENs) are heterogeneous in clinical course, biology, and outcomes. The NETPET score predicts survival by scoring uptake on dual [Ga]DOTATATE and [F]FDG PET/CT scans. We aimed...
10.
Alsadik S, Gnanasegaran G, Chen L, Quigley A, Mandair D, Toumpanakis C, et al.
J Neuroendocrinol
. 2022 Nov;
34(11):e13210.
PMID: 36399420
The aim of this study was to evaluate the efficacy and safety of Lu-DOTATATE therapy in advanced metastatic disease. A retrospective analysis of 395 patients (180 female, 215 males, mean...